Drugs / Onercept
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00090129 | Sep 2004 → Jun 2005 | psoriatic arthritis | EMD Serono | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onercept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00090129 ↗ |
| Known as | R-HTBP-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107911 ↗ |
| Action | Inhibit | “Onercept was shown in preclinical studies to inhibit TNF-α” PMID 20718590 ↗ Oct 2010 |
| Modality | Protein / enzyme biologic | “a tumor necrosis factor binding protein” PMID 20718590 ↗ Oct 2010 |
| Route | Subcutaneous | “Onercept will be administered subcutaneously three times a week at a dose of 150 mg” NCT00090129 ↗ |
| Target | TNF | “Onercept was shown in preclinical studies to inhibit TNF-α” PMID 20718590 ↗ Oct 2010 |